Diagnos Announces Closing of Oversubscribed $4 Million Brokered Private Placement Led by Centurion One Capital

Executive Summary

• Diagnos Inc. successfully closed an upsized private placement of 13,337,262 units at $0.30 per unit, generating gross proceeds of $4,001,178.60.
• Net proceeds will be used to advance regulatory filings with Health Canada and the FDA, accelerate product development, and support business‑development and general corporate activities.
• The offering included an over‑allotment option, a cash commission of $153,974.40, 666,863 units issued as a corporate finance fee, and 513,248 broker warrants; related‑party directors/officers purchased 316,665 units under MI 61‑101 exemptions.

Key Details

• Units sold: 13,337,262 (including over‑allotment).
• Issue price: $0.30 per unit.
• Gross proceeds: $4,001,178.60.
• Lead agent/bookrunner: Centurion One Capital Corp. (sole bookrunner).
• Legal counsel: Borden Ladner Gervais LLP (Diagnos); MLT Aikins LLP (Centurion One Capital).
• Unit composition: 1 common share + 1 share purchase warrant per unit.
• Warrant terms: Each warrant allows purchase of one additional share at $0.40 for 18 months post‑closing.
• Hold period: Statutory hold of 4 months + 1 day (ends 2026‑04‑06) on shares and warrants.
• Commission paid: $153,974.40 cash to lead agent.
• Corporate finance fee: 666,863 units issued to the company as a fee.
• Broker warrants: 513,248 broker warrants issued; each confers right to acquire a unit at the issue price any time before 2027‑06‑06.
• Related‑party participation: Two directors and one officer purchased 316,665 units; transaction relied on MI 61‑101 exemptions (no formal valuation or minority approval required).
• Use of proceeds: Regulatory affairs (Health Canada & FDA), product development acceleration, business development, and general corporate purposes.

Notable Quotes

“DIAGNOS is very pleased to announce the closing of this oversubscribed financing… The net proceeds will support the advancement of key regulatory initiatives with Health Canada and the FDA, the acceleration of product development, and the expansion of commercial deployments.” – André Larente, President